by Fred Dumais | Apr 28, 2022 | News Release
MONTREAL, QUEBEC , April 28, 2022 – Valeo Pharma Inc. (TSX:VPH, OTCQB: VPHIF, FSE:VP2) (“Valeo” or the “Company”), a Canadian pharmaceutical company, today announces the results of the proposals submitted to shareholders at its annual meeting of shareholders held on...
by Fred Dumais | Apr 25, 2022 | News Release
MONTREAL, QUEBEC , April 25, 2022 – Valeo Pharma Inc. (TSX:VPH, OTCQB: VPHIF, FSE:VP2) (“Valeo” or the “Company”), a Canadian pharmaceutical company, announced today that Steve Saviuk, Valeo’s Chief Executive Officer, will present a corporate overview and provide a...
by Fred Dumais | Apr 19, 2022 | News Release
MONTREAL, QUEBEC, April 19, 2022 – Valeo Pharma Inc. (TSX:VPH, OTCQB: VPHIF, FSE: VP2) (“Valeo” or the “Company”), a Canadian pharmaceutical company, is pleased to announce that the 12% Convertible Unsecured Subordinated Debentures (the “Debentures”)...
by Fred Dumais | Mar 28, 2022 | News Release
The Company’s shares and warrants to start trading on March 29th, 2022 MONTREAL, QUEBEC , March 28, 2022 – Valeo Pharma Inc. (TSX:VPH, OTCQB:VPHIF, FSE:VP2) (“Valeo” or the “Company”), a Canadian pharmaceutical company, announced today that it has received final...
by Fred Dumais | Mar 24, 2022 | News Release
Q1-22 revenues of $4.2 million, up 128% over Q1-21 Q1-22 gross margins of $1.4 million, up 266% over Q1-21Public reimbursement secured in key provinces for Enerzair, Atectura and Redesca$25.0 million convertible debenture financing completed MONTREAL,...
by Fred Dumais | Mar 22, 2022 | News Release
Canadian provincial public reimbursement now complete for Redesca with the addition of British Columbia Enerzair Breezhaler and Atectura Breezhaler reimbursement also secured for Saskatchewan and Prince Edward Island MONTREAL, QUEBEC , March 22, 2022 – Valeo Pharma...
